Introduction
Percutaneous mitral valve repair with MitraClip (Abbott, Santa Clara, CA, USA) remains a widely used tool for the treatment of functional mitral regurgitation (FMR), despite the absence of randomized trials comparing invasive vs. conservative management. Many real-world registries have reported favourable results, including high procedural success rates, low procedural complications, and functional status improvement.
1,2
Moreover, MitraClip has been shown to improve left ventricular (LV) dimensions and function in several patient cohorts.
1,3 -5 Previous studies have consistently reported the association between left ventricular reverse remodelling (LVRR) and better outcomes in patients with heart failure (HF) undergoing different treatments. 6 -11 However, the prognostic role of LVRR in patients who received MitraClip has never been investigated.
The purpose of this large multicentre registry was to explore the impact of LVRR on 2-year clinical outcomes of patients with FMR undergoing percutaneous edge-to-edge mitral valve repair and to report independent predictors of LVRR post-MitraClip.
Methods

Study population
This is a retrospective registry including consecutive patients undergoing successful MitraClip procedure due to significant [>=3+] FMR between December 2009 and June 2016 at three Italian centres (Spedali Civili of Brescia, San Raffaele Hospital of Milan and Azienda Ospedaliero-Universitaria Pisana of Pisa). All patients included in the present analysis were on optimal medical therapy [including cardiac resynchronization therapy (CRT) if indicated] for at least 3 months before MitraClip procedure. 12 In order to exclude the presence of silent coronary artery disease progression, all patients underwent coronary angiography within 3 months before the MitraClip implantation.
Exclusion criteria are reported in the online supplementary Table S1 . A team of specialists including clinical and interventional cardiologists, cardiac surgeons and anaesthetists discussed all cases.
The local ethics committee at each centre approved the use of clinical data for the study, and all patients provided written informed consent.
Data collection
Demographic, clinical and procedural data were assessed for quality and entered into a dedicated computerized database.
Echocardiographic data were separately analysed by two expert echocardiographers at each centre and reviewed by a third reader for consensus if there was disagreement.
MR was defined as severe (4+) if effective regurgitant orifice area (EROA) was ≥ 0.20 mm 2 or regurgitant volume (RV) was ≥ 0.30 mL; quantification of mild MR (1+) was made measuring the vena contracta width (<3 mm). 12 Left ventricular dimensions and LV ejection fraction (LVEF) were assessed according to previous recommendations. 13 
Definitions
Ischaemic FMR was defined as the presence of dilated cardiomyopathy due to previous myocardial infarction and/or previous coronary artery bypass graft/percutaneous coronary intervention, or associated with severe coronary artery disease not suitable for revascularization. Non-ischaemic FMR was defined as the presence of dilated cardiomyopathy of unknown cause.
Device success was defined as a reduction in MR after MitraClip of at least one degree.
LVRR was defined as a change in LV end-systolic volume (LVESV) of ≥ 10% from baseline to 6-month follow-up, as assessed at transthoracic echocardiography using biplane Simpson's method. 14, 15 The change in LVESV was calculated as follows: (LVESV baseline − LVESV 6 months )/LVESV baseline × 100. The study population was divided into two groups according to the presence or absence of LVRR (LVRR and non-LVRR).
Endpoints
Residual MR post-MitraClip was evaluated immediately after MitraClip procedure. Functional status, using the New York Heart Association (NYHA) classification, and echocardiographic parameters [MR degree, LVEF, LV end-diastolic volume (LVEDV), LVESV and systolic pulmonary artery pressure (SPAP)] were assessed at 30-day, 6-month and 1-year follow-up.
Clinical outcomes, evaluated at 2-year follow-up, included: (i) all-cause mortality; (ii) cardiovascular (CV) mortality; (iii) hospitalization due to HF; and (iv) the composite endpoint of CV death or HF hospitalization.
Statistical analysis
The normal distribution of continuous variables was explored with Kolmogorov-Smirnov and the Shapiro-Wilk tests. Continuous variables following a normal distribution are reported as mean ± standard deviation and were compared using the Student's t-test, whereas those not following a normal distribution are presented as median and interquartile range (IQR) and were compared with the Mann-Whitney U test. Categorical variables are reported as counts and percentages and were compared using the 2 or Fisher exact tests, as appropriate. Comparisons between dependent continuous variables at different time-points were performed with Friedman test.
The survival rate free from clinical endpoints at 2 years was estimated using the Kaplan-Meier method, and differences between LVRR and non-LVRR groups were calculated using the log-rank test.
The proportionality assumptions were checked by visual estimation after plotting the log cumulative hazard vs. (log) time at follow-up after the index procedure and by applying a test for non-proportional hazards using Schoenfeld residuals, which failed to reject the null hypothesis that clinical endpoints were affected by time. Therefore, a multivariate Cox regression analysis including baseline variables differently distributed at an alpha level of 0.10, was performed to evaluate whether LVRR was an independent predictor of clinical outcome. Each result was expressed as hazard ratio (HR) and corresponding 95% confidence interval (CI). Baseline variables differently distributed at an alpha level of 0.10 were entered in a stepwise logistic regression model in order to calculate independent predictors of LVRR. Each result was reported as odds ratio (OR) and corresponding 95% CI.
For all analyses, a two-sided P < 0.05 was considered to be significant. All statistical analyses were performed using the SPSS software, version 21 (SPSS Inc., Chicago, IL, USA).
Results
Of the 283 patients undergoing MitraClip procedure due to FMR during the observation period, 99 subjects were excluded from the present analysis for the following reasons: 6 patients underwent CRT implantation during the 3-month period before (n = 4) or after the MitraClip procedure (n = 2); 5 patients had an unsuccessful procedure (lack of MR reduction post-MitraClip); 33 subjects died, and 6 underwent cardiac transplantation within 6 months after the procedure; 25 subjects missed their 6-month follow-up; and 24 had missing LVESV measurements for LVRR calculation at baseline (n = 5), 6 months (n = 11), or both (n = 8).
Among the 184 patients included in the analysis, 79 (42.9%) experienced LVRR after MitraClip. Median LVESV change from baseline to 6 months was 4.5% (IQR −0.9% to 1.9%) in the overall population; 23% (IQR 15-31%) and −6% (IQR −20% to 2%) in the LVRR and non-LVRR group, respectively (P < 0.001).
Baseline characteristics
Baseline features of LVRR as compared to non-LVRR subjects are reported in Table 1 .
Compared with the LVRR group, non-LVRR patients were more likely to be males (83.8% vs. 60.8%; P = 0.001) and to have an ischaemic aetiology of MR (55.2% vs. 35.4%; P = 0.011), or history of HF hospitalization during the 6-month period before the procedure (89.5% vs. 74.7%; P = 0.010). Moreover, a trend towards a lower frequency of diabetes was observed in the LVRR vs. non-LVRR group (25.3% vs. 39.0%; P = 0.058). As for the echocardiographic parameters, patients who experienced LVRR had significantly lower LV dimensions compared with non-LVRR patients [LV end-diastolic diameter (LVEDD) 66 ± 9 vs. 70 ± 10 mm; P = 0.006; LV end-systolic diameter (LVESD) 54 ± 11 vs. 58 ± 10 mm; P = 0.027) ( Table 2 ).
Procedural data
No differences were noted between the two groups in the number of devices employed and procedural complications. A trend towards a more frequent use of mechanical and/or pharmacological supports during the procedure was observed in the non-LVRR vs. LVRR group. There were no significant differences in residual MR post-MitraClip ( Table 3) . Of note, a higher rate of MR reduction post-MitraClip was noted in non-LVRR vs. LVRR patients (−2.52 ± 0.76 vs. −2.31 ± 0.84; P = 0.08).
. 
Functional and echocardiographic results
A significant improvement in NYHA functional class from baseline up to 1-year follow-up was observed in both groups ( Figure 1 ). Mitral regurgitation degree did not differ significantly between groups during the follow-up (Figure 2) . A similar rate of MR ≤ 2+ was observed in LVRR and non-LVRR patients at 30 days (84.3% vs. 77.7%; P = 0.301), 6 months (80.7 vs. 73.1; P = 0.294) and 1 year (78.4% vs. 69.9%; P = 0.296).
A significant LVEF increase from baseline to 1-year follow-up was noted in the LVRR group, whereas a significant worsening was observed in non-LVRR patients ( Figure 3A) . Accordingly, LVEDV and LVESV changed from baseline to 1 year, decreasing significantly in the LVRR group and increasing progressively in the non-LVRR group ( Figure 3B and 3C). Finally, a significant SPAP reduction from baseline to 1 year was observed in both groups ( Figure 3D ). Of note, at 1 year, SPAP was significantly lower in the LVRR vs. non-LVRR cohort.
Long-term clinical outcomes
LVRR patients showed a higher 2-year survival from all-cause mortality as compared to non-LVRR patients (87.3% vs. 75.2%; log-rank P = 0.039) ( Figure 4A A trend towards improved survival from CV mortality at 2 years was noted in the LVRR vs. non-LVRR group (92.4% vs. 83.8%; log-rank P = 0.070) ( Figure 4B) . LVRR was not associated with the adjusted relative risk of CV death (HR 0.49; 95% CI 0.18-1.33; P = 0.161).
Survival from HF hospitalization and from the composite endpoint of HF hospitalizations or CV death at 2-year follow-up were significantly higher in LVRR vs. non-LVRR patients (77.2% vs. 60%; log-rank P = 0.020 and 74.7% vs. 55.2%; log-rank P = 0.012, respectively) ( Figure 4C and 4D) . 
Predictors of left ventricular reverse remodelling
Female gender and absence of HF hospitalization during the 6 months before MitraClip were associated with an almost three-fold increased probability of showing LVRR. Patients without diabetes mellitus, with non-ischaemic aetiology of MR and LVEDD < 75 mm had a roughly two-fold increased probability of developing LVRR ( Table 4) .
Discussion
The present study shows that: (i) LVRR, defined as LVESV decrease ≥ 10%, occurred in 43% of a real-world population who underwent successful MitraClip implantation 6 months previously; (ii) LVRR was significantly associated with clinical outcomes in patients with FMR undergoing MitraClip: a roughly 50% risk reduction of 2-year adverse events (mortality, HF hospitalization and the composite of CV mortality and HF hospitalization) was observed in patients who experienced LVRR; (iii) female gender, absence of diabetes mellitus, freedom from HF hospitalization before MitraClip (< 6 months), non-ischaemic aetiology of MR and LVEDD < 75 mm were independent predictors of favourable LV remodelling after MitraClip.
The incidence of LVRR in other clinical settings (i.e. after coronary revascularization in patients with myocardial infarction, after medical therapy or CRT in HF patients) is extremely variable (39-67%), 6 ,7,14 -16 likely because of the different patient characteristics and definitions adopted. We applied one of the most widely used definitions, i.e. the change in LVESV ≥10%, 14, 15 and less than 50% of our MitraClip population experienced LVRR.
Previous studies have consistently reported the prognostic role of LVRR.
6 -11,14-16 In the Acute Myocardial Infarction Contrast Imaging (AMICI) multicentre study, a change in LVESV > 10% after percutaneous coronary intervention was associated with imporved survival rates at 2-year follow-up. 16 Moreover, a favourable LV remodelling related to a survival advantage has been described in HF patients treated with beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and ivabradine. 8 -10 Finally, many studies have demonstrated an association between LVRR and clinical outcomes after CRT. 6, 7, 14, 15 The Resynchronization Reverses Remodelling in Systolic Left Ventricular Dysfunction (REVERSE) trial showed a 14% reduction in mortality for every 10% reduction in LVESV. 6 In the Multicenter Automatic Defibrillator Implantation Trial (MADIT), each 10% decrease in LVEDV was associated with a 40% reduction in the risk of death or HF. 7 Left ventricular reverse remodelling after percutaneous edge-to-edge mitral valve repair has been extensively reported.
1,3 -5 In the percutaneous arm of the Endovascular Valve Edge-to-Edge Repair Study (EVEREST II), a significant reduction in LV volumes and a significant improvement of LVEF were observed at 1-year follow-up.
1 Similarly, Tamarasso et al. 4 reported a significant increase in mean LVEF values with a concomitant reduction in LVEDD and LVEDV in 109 patients undergoing MitraClip due to FMR. Auricchio et al. 5 described a significant change in LV volumes and LVEF at 6 and 12 months after MitraClip in 51 CRT non-responder patients. However, LVRR after MitraClip has been so far reported in a descriptive fashion, in terms of mean change in LV volumes between time-points without information about frequency and prognostic significance of this phenomenon.
To the best of our knowledge, this is the first study that reports the incidence of LVRR and its association with clinical outcomes in FMR patients undergoing MitraClip implantation. In our population, LVRR was associated with a dramatic reduction in the relative risk of mortality, HF hospitalization and composite endpoint. In the non-LVRR group, LVEF significantly decreased and LV volumes progressively increased from baseline to 1-year follow-up and this probably translated into a worse prognosis. However, NYHA functional class and pulmonary hypertension significantly improved during the follow-up, regardless of LVRR.
We could speculate that the turning point to a favourable long-term prognosis after MitraClip is LVRR. In patients who did not experience LVRR, we can expect symptom and functional status improvement due to MR and pulmonary pressure reduction, but we probably cannot expect a prognostic benefit.
In our population, non-ischaemic aetiology of MR and absence of diabetes were associated with a 2.5-fold and a 2.1-fold increased probability of LVRR, respectively. Non-ischaemic cardiomyopathy . has already been reported as a predictor of LVRR in patients receiving CRT. 17, 18 It is known that patients with a ventricular substrate without ischaemic area or 'scar' are more likely to develop LVRR.
17,18
Previous studies exploring the influence of diabetes on LVRR after CRT provided contradictory results. Several studies reported a more pronounced improvement in LV function after CRT among non-diabetic vs. diabetic patients. 19, 20 Conversely, subgroup analyses from randomized clinical trials showed improvement in LV performance regardless of diabetes status. 21, 22 The frequent association between diabetes and ischaemic cardiomyopathy has previously been reported as an explanation of the limited LVRR in diabetic patients 19 ; however, in our multivariable analysis that included MR aetiology (which can be considered as a surrogate of cardiomyopathy aetiology: ischaemic vs. non-ischaemic), diabetes turned out to be an independent predictor of LVRR. Nevertheless, several diabetes-related pathophysiological mechanisms might be involved in the association between non-LVRR and diabetes, including reduced microvascular blood flow, increased myocardial fat and interstitial fibrotic tissue content, advanced glycation end-product deposition, neurohumoral and autonomic functional changes.
19
Freedom from prior HF hospitalization and LVEDD < 75 mm were related to a 2.8-and 2.2-fold increased probability of LVRR, respectively. Both parameters have previously been reported as predictors of LVRR after CRT. 17, 23 They are probably expression of a less advanced cardiomyopathy.
Previous data on LVRR after MitraClip in FMR patients with advanced HF were contrasting.
Franzen et al. 24 showed a significant reduction in LV volumes and an increase in LVEF at 6 months in 50 patients with end-stage HF. Conversely, in the Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology, patients with FMR showed no LVRR. The authors explained this finding with the advanced HF stage of the patients. 25 These results are supported by other small studies including patients with refractory HF. 26, 27 All above observations suggest that an early intervention on FMR may be associated with a favourable LV remodelling.
Female gender remains the less explained predictor of LVRR. A meta-analysis including approximately 150 000 patients from 11 studies showed that women obtain a greater LV improvement after CRT compared with men. 28 In several studies, female rates were significantly higher among patients who developed LVRR after medical therapy or CRT compared with those who did not. 17, 18 However, gender-based analyses from real-world registries including MitraClip patients showed similar LVEF and LV volumes changes from baseline to 1-year follow-up in males and females. 29, 30 Importantly, all our selected patients received a successful (at least one degree) MR reduction after MitraClip. The improvement in MR degree, assessed immediately after the procedure, was apparently higher in the non-LVRR group. However, it should be taken into account that non-LVRR patients were more likely to receive pharmacological and/or mechanical supports during the intervention, and this may account for a possible underestimation of MR degree post-MitraClip. Indeed, this difference disappeared at 30 days when MR degree and MR reduction no longer differed between groups. Thus, LVRR occurred independently of MR, which means that a reduction of at least (even only) one MR degree could be associated with positive remodelling in patients with specific favourable features (female sex, no diabetes, no recent HF hospitalization, no ischaemic aetiology of MR, reduced LV diameter).
Limitations
Our study has the inherent limitations of its retrospective design. Moreover, as a non-randomized study, several confounding factors could have influenced our results; nevertheless, the inclusion of consecutive patients and the statistical adjustment for baseline imbalance should have minimized potential selection bias.
The sample size is relatively small and the echocardiographic follow-up limited (mid-term), thus our results should be reproduced in larger populations with a longer echocardiographic follow-up. Several echocardiographic parameters such as LV longitudinal strain, right ventricular and left atrial dimension and function are lacking. Moreover, echocardiographic data have not been reviewed by an independent core laboratory. However, all analyses were conducted by dedicated, highly experienced physicians utilizing validated methods and were based on consensus. Finally, specific information about non-ischaemic aetiology of MR (i.e. toxic, myocarditis) is lacking. Instead, in the context of ischaemic aetiology of MR, no data regarding the scar burden are available.
Conclusions
Left ventricular reverse remodelling was associated with roughly a 50% reduction in the relative risk of 2-year mortality, HF hospitalization and CV death or HF hospitalization in patients with FMR undergoing percutaneous edge-to-edge mitral valve repair. Independent predictors of LVRR post-MitraClip were: gender (female), absence of diabetes, freedom from prior HF hospitalization, non-ischaemic aetiology of MR, and baseline LVEDD < 75 mm.
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